<DOC>
	<DOCNO>NCT01373346</DOCNO>
	<brief_summary>We graft concept metabolic surgery ( long limb Roux-en Y reconstruction ) gastric cancer surgery . This study aim investigate safety efficacy long limb Roux-en Y reconstruction gastrectomy non-obese type II diabetes gastric cancer .</brief_summary>
	<brief_title>Safety Efficacy Long Limb Roux-en Y Reconstruction</brief_title>
	<detailed_description>Type II diabetes world increase rapidly , know patient type II diabetes morbid obesity underwent bariatric surgery resolution impair glucose metabolism . In Asia , type II diabetes morbidly obese still , controversy whether metabolic surgery effective non-morbid obese patient . As life expectancy increase , number patient gastric cancer T2DM increase well . Recently , study outcome T2DM gastrectomy conventional reconstruction non-obese gastric cancer patient . ( Kim JW et al , World J Gastroenterol 2012 ; 18:49 ) The study large-series retrospective study include 400 patient result regard DM improvement satisfactory . Based previous result , need find effective way resolve type II diabetes gastrectomized patient gastric cancer .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Pathologically confirm gastric cancer potentially curable state Nonobese ( Body mass index : le 30 kg/m2 ) Have history Type 2 DM 6 month ( diagnose ADA criterion ) 1 . HBA1c : 6.5 % , Fasting glucose : 126 mg/dl ( 7.0mmol/L ) 2h plasma glucose : 200mg/dl OGTT classic symptom hyperglycemia hyperglycemic crisis , random plasma glucose : 200mg/dl 2 . AntiGAD antibody ( ) , Antiislet antibody ( ) Cpeptide level : 1ng/ml Patient receive noncurative operation Patient le one year life expectancy Pregnant patient Acute inflammation status patient Chronic renal disease patient ( Serum creatin level : 1.5mg/dl ) Chronic liver disease patient ( Serum AST ALT level : twice upper limit normal range ) Have history receiving medication dipeptidyl peptidase IV ( DPP IV ) inhibitor glucagon like peptideI ( GLPI ) analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>type II diabetes</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Long limb Roux-en Y</keyword>
</DOC>